Specifically, they described a higher proportion of homozygous patients for CYP2C:TG compared to the reference population (New Zealand European) among patients with objective GERD, despite treatment with omeprazole (≥40 mg/day) for a minimum of 8 weeks (p = 0.03). The gene discussed is CYP2C19; the disease is gastroesophageal reflux disease.